{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-22-007571","form_type":"8-K","ticker":"DLB","cik":"0001308547","company_name":"Dolby Laboratories, Inc.","filed_at":"2022-11-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.080593+00:00","generated_at":"2026-06-21T16:28:45.938006+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Dolby reports Q4 revenue $278.2M (-2% YoY) and GAAP EPS $0.28; FY revenue $1.25B; dividend $0.27","bullets":["Q4 FY2022 revenue $278.2M (down 2.4% YoY from $285.0M); GAAP net income $27.8M ($0.28 EPS) vs $44.2M ($0.42) a year ago.","Full year FY2022 revenue $1.25B (down 2.3% from $1.28B); GAAP net income $184.1M ($1.81 EPS) vs $310.2M ($2.97) prior year.","Non-GAAP Q4 EPS $0.54 vs $0.58 YoY; FY non-GAAP EPS $3.14 vs $3.66; operating cash flow $318.6M, down from $447.8M.","Declared $0.27 per share cash dividend, payable Dec 8, 2022 to holders of record Nov 30; unchanged from prior rate."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-22-007571","json":"https://secwatch.observer/filing/0001171843-22-007571.json","markdown":"https://secwatch.observer/filing/0001171843-22-007571.md","text":"https://secwatch.observer/filing/0001171843-22-007571.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1308547/000117184322007571/0001171843-22-007571-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1308547/000117184322007571/f8k_111722.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T16:28:45.938006+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"63bfdd4de5afe9bce641f6619effaf7c49569df6","claim":"Dolby Laboratories, Inc. reported Full Year Fiscal 2022 results: revenue $1.25 billion, net income $184.1 million, EPS $1.81 per diluted share.","evidence_excerpt":"Total revenue was $1.25 billion, compared to $1.28 billion for the full year of fiscal 2021. GAAP net income was $184.1 million, or $1.81 per diluted share, compared to GAAP net income of $310.2 million, or $2.97 per diluted share, for the full year of fiscal 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1308547/000117184322007571/0001171843-22-007571-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full Year Fiscal 2022"},{"label":"Revenue","value":"$1.25 billion"},{"label":"Net income","value":"$184.1 million"},{"label":"EPS","value":"$1.81 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"a620f0651394bb94b47df96c07f0f0769ffe53d8","claim":"Dolby Laboratories, Inc. reported Fourth Quarter Fiscal 2022 results: revenue $278.2 million, net income $27.8 million, EPS $0.28 per diluted share.","evidence_excerpt":"Total revenue was $278.2 million, compared to $285.0 million for the fourth quarter of fiscal 2021. GAAP net income was $27.8 million, or $0.28 per diluted share, compared to GAAP net income of $44.2 million, or $0.42 per diluted share, for the fourth quarter of fiscal 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1308547/000117184322007571/0001171843-22-007571-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Fourth Quarter Fiscal 2022"},{"label":"Revenue","value":"$278.2 million"},{"label":"Net income","value":"$27.8 million"},{"label":"EPS","value":"$0.28 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}